280例乳腺癌患者贫血情况临床分析

Analysis of anemia incidence for 280 patients with breast cancer

目的:研究乳腺癌患者初诊时和治疗前后的血红蛋白(Hb)变化、贫血发生情况及其与临床分期、年龄和治疗等方面的关系。方法:对我院近10年期间住院的280例乳腺癌患者进行回顾分析,研究治疗前后Hb值的变化和贫血的发生例数,并按临床分期和年龄分组进行分析。结果:(1)280例患者初诊时贫血发生率25.0%,治疗前后总发生率42.9%。Ⅰ级74例(61.6%),Ⅱ级38例(31.7%),Ⅲ级6例(5.0%),Ⅳ级2例(1.7%)。(2)CMF方案化疗贫血发生率30.4%(17/56),而CAF方案为26.8%(14/41)。(3)Ⅱ期、Ⅲ期和Ⅳ期患者治疗后的Hb值明显低于治疗前(P<0.05);随着分期的提高,贫血发生率增高,但无统计学意义(P>0.05)。(4)贫血发生与年龄密切相关(P<0.01),老年患者贫血发生率61.5%,明显高于非老年患者的37.2%(P<0.01)。(5)贫血程度NCI分级则与临床分期、年龄无明显相关。结论:乳腺癌患者有较高的贫血发生率,贫血的发生与临床分期和治疗有一定相关性,尤其与患者年龄密切相关,老年患者更易发生贫血。

Objective：To study the anemia incidence for 280 patients with breast cancer,and analyze correlation between anemia and age, clinical staging, therapy. Methods： To analyze both pre-therapy and post-therapy patients＇ hemoglobin （Hb） and study the anemia incidence for 280 patients with breast cancer during ten years （ from 1996 to 2005 ）. Results： （ 1 ） The anemia incidence of 280 patients with breast cancer was 25.0% and 42. 9% respectively in pre-therapy and post-therapy. （2）The anemia incidence were 30. 4% and 26. 8% respectively in breast cancer with CMF or CAF therapy. （3） The Hb levels of Ⅱ , Ⅲ and Ⅳ stagings patients in post-therapy were lower than pre-therapy （ P 〈 0.05 ）. （4） The incidence of anemia had closed correlation with age and clinical staging, and the older patients were prone to anemia（ P 〈 0. 01 ）. （5）The anemia NCI phases had no correlation with age and clinical stagings. Conclusion：The anemia incidence was higher with breast patients, the anemia was closed correlation with age, clinical staging and therapy. The elderly patients with breast cancer were prone to anemia.